Q2 2025 Bruker Corp Earnings Call Transcript
Key Points
- Bruker Corp (BRKR) is poised for significant margin improvement and double-digit EPS growth in fiscal year 2026 due to major cost reduction initiatives.
- The company is expanding its cost savings initiative, expected to reduce annual costs by $100 million to $120 million, which will improve margins and profitability.
- Bruker Corp (BRKR) has strong positions in microbiology and infection diagnostics, with promising growth in the MALDI Biotyper and Molecular Diagnostics business.
- The company is leveraging its backlog effectively, maintaining a 6.5-month backlog, which provides some cushion for future revenue.
- Bruker Corp (BRKR) is optimistic about the potential recovery in fiscal year 2026, driven by anticipated improvements in US and China academic funding and biopharma investments.
- Bruker Corp (BRKR) reported a 0.4% year-over-year revenue decline in Q2 2025, with organic revenues decreasing by 7.0%.
- The company faced significant headwinds from US tariffs, foreign currency fluctuations, and economic uncertainties, impacting margins and profitability.
- Bruker Corp (BRKR) lowered its fiscal year 2025 guidance, expecting flat constant exchange rate revenue growth and a 2% to 4% organic revenue decline.
- The company's book-to-bill ratio was in the mid-0.9% range, indicating weaker demand and delayed investments in biopharma and industrial research instrumentation.
- Bruker Corp (BRKR) anticipates continued challenges in the third quarter of 2025, with expected mid- to high single-digit percentage declines in organic revenue.
Good day, and welcome to Bruker Corporation's second quarter 2025 earnings conference call. (Operator Instructions) Please note, this event is being recorded.
I would now like to turn the conference over to Joe Kostka, Director of Investor Relations. Please go ahead.
Good morning. I would like to welcome everyone to Bruker Corporation's second quarter '25 earnings conference call. My name is Joe Kostka, and I'm the Director of Bruker Investor Relations. Joining me on today's call are our President and CEO, Frank Laukien, and our EVP and CFO, Gerald Herman.
In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the Events and Presentations section of Bruker's Investor Relations website.
During today's call, we will be highlighting non-GAAP financial information. Reconciliations of our non-GAAP to GAAP financial measures are included in our earnings release and are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
